K.Papp Clinical Research Inc.

Waterloo, Ontario N2J1C4

0 studies enrolling now · 32 studies all time

What they study most

Acne, Acne Vulgaris, Alopecia Areata, Atopic Dermatitis, Chronic Plaque Psoriasis, Dermatitis, Atopic, Moderate Plaque Psoriasis, Onychomycosis, Palmoplantar Pustulosis (PPP), Plaque Psoriasis, Plaque-type Psoriasis, Psoriasis

Studies at this site

• Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis — Completed
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) — Completed
• A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis — Completed
• Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis — Completed
• This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is — Completed
• Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis — Completed
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed
• Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1% — Completed
• CP-690-550 Ointment For Chronic Plaque Psoriasis — Completed
• Topical CP-690,550 For Chronic Plaque Psoriasis — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) — Completed
• A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis — Completed
• Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) — Completed
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis — Completed
• Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis — Completed
• Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis — Completed
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis — Completed
• A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel — Completed
• Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis — Stopped early
• Tofacitinib Ointment For Chronic Plaque Psoriasis — Completed
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis — Completed
• A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis — Completed
• Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice — Completed
• Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy — Completed